FDA Policy/General

Symposium on Clinical Trials, Bioequivalence and Pharmacovigilance

U.S., U.K. and Canadian drug regulators are announcing a 6/2-4 joint international symposium to discuss evolving regulatory expectations for clinical trials, bioequivalence studies and pharmacovigilance, according to a meeting notice posted by FDA. The three-day FDA/MHRA/Health Canada Symposium is expected to draw regulators, clinical investigators, trial sponsors, contract research organizations, pharmaceutical and biotechnology companies, academics, and patient advocacy groups.

FDA’s notice says the symposium will focus on current and emerging regulatory issues affecting drug development and postmarket safety oversight. A major theme will be implementation of the revised International Council for Harmonization guideline ICH E6(R3), which emphasizes a shift from compliance-driven oversight to a quality-focused approach to clinical trial conduct. Regulators plan to discuss quality-by-design principles and risk-proportionate strategies aimed at improving trial efficiency while protecting participants, it says.

The agenda also includes sessions on innovative trial designs, including regulatory expectations for decentralized and pragmatic trials, risk-based quality management, and the use of real-world data. Experts are expected to outline how inspectors and reviewers are evaluating these approaches, the notice says.

Bioequivalence will be another focus area, with regulators presenting case studies on common deficiencies identified during inspections and offering guidance on improving application quality, data integrity and risk management in bioanalytical and clinical studies.

Pharmacovigilance sessions will cover regulatory updates, inspection trends, and international efforts to harmonize safety oversight, including the use of remote assessments and collaborative inspection models. Agencies also plan to share metrics on inspection findings and compliance challenges.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome